Literature DB >> 820707

Secretion of alpha subunit of glycoprotein hormones by pituitary adenomas.

I A Kourides, B D Weintraub, S W Rosen, E C Ridgway, B Kliman, F Maloof.   

Abstract

In 60 patients with pituitary adenomas, the serum concentration of the alpha subunit of the glycoprotein hormones (serum alpha) was measured by a sensitive and specific radioimmunoassay. Five patients had markedly elevated serum alpha prior to therapy (range 14.5-23.0 ng/ml). These 5 patients included 2 hyperthyroid men with inappropriately high serum thyrotropin, one of whom also had acromegaly, a man with hyperprolactinemia and elevated cerebrospinal fluid alpha, a postmenopausal woman with low serum gonadotropins and hyperprolactinemia, and a man with central hypothyroidism and hypogonadism. Three of the 5 were restudied after therapy; serum alpha in these three decreased from19.5 to 10.6, 23.0 to 2.0, and 17.0 to 12.0 ng/ml. Alpha in these 3 patinets' serum eluted similarly to normal pituitary alpha by gel chromatography. The other 55 patinets, including twenty with acromegaly, fifteen with galactorrhea, and two with Nelson's syndrome, had serum alpha.less than 0.5-5.0 ng/ml. In addition, 22 patients with "empty sella" syndrome (no pituitary tumor) had alpha less than 0.5-5.0 ng/ml. Normal men and premenopausal women had serum alpha concentrations of less than 0.5-2.5 ng/ml; normal postmenopausal women, 1.0-7.0 ng/ml; and patients with primary hypothyroidism, 0.7-9.0 ng/ml. The decreased alpha response to thyrotropin and luteinizing hormone-releasing hormones (TRH and LHRH) implied a relative autonomy of pituitary tumor alpha secretion; the mean alpha increment in the 5 patients with elevated serum alpha was 15% after TRH administration and 10% after LHRH. Normal individuals and patients with primary hypothyroidism demonstrated greater mean per cent alpha increments after TRH or LHRH. In certain patients with an enlarged sella turcica, an elevated serum alpha with little or no increase in secretion after TRH and LHRH may suggest the presence of pituitary tumor.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 820707     DOI: 10.1210/jcem-43-1-97

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  Thyroid stimulating and gonadotrophic hormones in pituitary adenomas without clinical or serological abnormality.

Authors:  E Hitchcock; C S Morris
Journal:  Histochem J       Date:  1986-06

2.  Immunohistochemical colocalization of growth hormone (GH) and alpha subunit in human GH secreting pituitary adenomas.

Authors:  R Y Osamura; K Watanabe
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

Review 3.  Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.

Authors:  Mansur E Shomali; Laurence Katznelson
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

4.  Secretion of neuron-specific enolase, prolactin, growth hormone, luteinising hormone and follicle stimulating hormone by "functionless" and endocrine-active pituitary tumours in vitro.

Authors:  N F Lawton; A J Evans; J D Pickard; S Perry; B Davies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-05       Impact factor: 10.154

5.  Regulation of hormone release by cultured cells from a thyrotropin-growth hormone-secreting pituitary tumor. Direct inhibiting effects of 3,5,3'-triiodothyronine and dexamethasone on thyrotropin secretion.

Authors:  S W Lamberts; R Oosterom; T Verleun; E P Krenning; H Assies
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

6.  beta-Endorphin: analgesic and hormonal effects in humans.

Authors:  K M Foley; I A Kourides; C E Inturrisi; R F Kaiko; C G Zaroulis; J B Posner; R W Houde; C H Li
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

7.  Genetically determined asynapsis, spermatogenic degeneration, and infertility in men.

Authors:  R S Chaganti; S C Jhanwar; L T Ehrenbard; I A Kourides; J J Williams
Journal:  Am J Hum Genet       Date:  1980-11       Impact factor: 11.025

8.  Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3'-triiodothyroacetic acid (TRIAC).

Authors:  P Beck-Peccoz; G Piscitelli; M G Cattaneo; G Faglia
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

9.  Thyrotropin-releasing hormone stimulation of adrenocorticotropin production by mouse pituitary tumor cells in culture: possible model for anomalous release of adrenocorticotropin by thyrotropin-releasing hormone in some patients with Cushing's disease and Nelson's syndrome.

Authors:  M C Gershengorn; C O Arevalo; E Geras; M J Rebecchi
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

10.  Metabolic clearance and secretion rates of subunits of human thyrotropin.

Authors:  I A Kourides; R N Re; B D Weintraub; E C Ridgway; F Maloof
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.